Format

Send to

Choose Destination
Free Radic Res. 2018 Sep;52(9):952-960. doi: 10.1080/10715762.2018.1500021. Epub 2018 Oct 18.

Leonurine ameliorates adriamycin-induced podocyte injury via suppression of oxidative stress.

Author information

1
a Department of Nephrology , the First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University , Nanjing , China.
2
b Department of Pharmacy , Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine , Shanghai , China.
3
c Department of Nephrology , Affiliated Nanjing Drum Tower Hospital, Nanjing University School of Medicine , Nanjing , China.

Abstract

Leonurine, a major bioactive component from Herba Leonuri, shows therapeutic potential in several diseases, including diabetes, cardiovascular disease, bovine mastitis and depression. In kidney, it was reported that leonurine was performing a protective effect in both acute kidney injury and renal fibrosis mice models. The aim of this study is to investigate the effect of leonurine in podocyte injury. In the mice model of adriamycin (ADR) -induced nephropathy, the application of leonurine significantly prevented early kidney damage, macrophage infiltration and proteinuria. Meanwhile, leonurine suppressed ADR-induced podocyte injury and reactive oxygen species (ROS) production. Consistent to in vivo results, leonurine prevented ADR-induced podocyte injury and ROS production in cultured human podocytes. All these results suggested that leonurine might suppress ADR-induced podocyte injury via inhibiting oxidative stress. Leonurine might be a novel therapeutic drug for prevention of glomerular diseases.

KEYWORDS:

Adriamycin; leonurine; oxidative stress; podocyte injury

PMID:
30334481
DOI:
10.1080/10715762.2018.1500021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center